Rather, an antibody targeting a DC specific surface marker, such as C-type lectin domain containing 9A (Clec9a), is conjugated to a tumor antigen and injected into patients to promote the delivery of immunogenic tumor antigens to key DC subsets [220,221,222]. This evidence concerns the gene CLEC9A and neoplasm.